00872cam2 2200253 450 E60020007247320190507105056.020110311d1903 |||||ita|0103 baitaIT<<2: >>Lettere di Vittorio AlfieriTorinoRomaMilanoParavia1903347 p.20 cm001E6002000724692001 Opere di Vittorio Alfieri ristampate nel primo centenario della morteAlfieri, Vittorio <1749-1803>AF00006793070292812ITUNISOB20190507RICAUNISOBUNISOB8503399E600200072473M 102 Monografia moderna SBNM850003514-2SI3399catenacciUNISOBUNISOB20110311110004.020190507105056.0rovitoLettere di Vittorio Alfieri1701689UNISOB02238nam 2200481 450 991077460800332120170701144453.01-78262-985-8(CKB)3710000001055705(MiAaPQ)EBC4803359(oapen)https://directory.doabooks.org/handle/20.500.12854/70699(EXLCZ)99371000000105570520170226h20172017 uy 0engurcnu||||||||rdacontentrdamediardacarrierAnti-aging drugs from basic research to clinical practice /edited by Alexander VaisermanCambridgeRoyal Society of Chemistry2017[Cambridge, England] :Royal Society of Chemistry,2017.©20171 online resource (592 pages) illustrations, tables1-78262-435-X 1-78262-660-3 Includes bibliographical references at the end of each chapters and index.Provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.--Source other than Library of Congress.Drug developmentAgingPreventionaging; diseaseDrug development.AgingPrevention.615.19Janac Sarahedt1461188Vaiserman AlexanderRoyal Society of Chemistry (Great Britain),MiAaPQMiAaPQMiAaPQBOOK9910774608003321Anti-aging drugs3664857UNINA